Clinical Trials Logo

Clinical Trial Summary

FMF is the most common periodic fever with a worldwide patient population estimated as 150,000, mainly located in the Eastern Mediterranean basin. colchicine is the established therapy of choice ,however, around 20.000 patients worldwide fail to respond or cannot tolerate therapeutic doses, thereby suffering from recurrent debilitating, severe, painful attacks of peritonitis, pleuritis and synovitis and are at risk to die from reactive amyloidosis .Mutation-induced reduction in pyrin/ marenostrin activity is thought to underlie the disease by leading to NALP3 inflammasome activation ,and thereby to IL-1β related burst of inflammation. The IL-1 receptor antagonist Kineret (Anakinra), seems to be the most appropriate response to the uncontrolled IL-1β elevation. Indeed, an increasing number of reports over the last few years indicate a good response to Kineret (Anakinra), in colchicine-resistant FMF ,also in children ,however, no controlled study has thoroughly evaluated the efficacy and safety of this treatment. Study outline: The study aims to run at the FMF centre in Sheba Medical Center, covering more than 10,000 patients. The study will evaluate the effect of recombinant IL-1 receptor antagonist, Kineret (Anakinra), on the frequency of FMF attacks in patients that, despite maximum tolerable dose of colchicine, present with more than one attack per month. The study is designed as a randomised, placebo-controlled, double-blind study. 50 patients will be randomised to treatment with either Kineret (Anakinra), or placebo treatment for 4 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01705756
Study type Interventional
Source Sheba Medical Center
Contact
Status Completed
Phase Phase 3
Start date November 2012
Completion date June 2015

See also
  Status Clinical Trial Phase
Recruiting NCT00658060 - Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients N/A
Withdrawn NCT05448391 - A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) Phase 2
Recruiting NCT05190991 - Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever Phase 2
Completed NCT00094900 - Interleukin-1 Trap to Treat Autoinflammatory Diseases Phase 2
Not yet recruiting NCT06033339 - Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology N/A
Recruiting NCT06338891 - Can Gluten/Wheat or Other Foods be Responsible for FMF Attacks
Recruiting NCT05596643 - Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever
Enrolling by invitation NCT02175589 - Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation Phase 2
Completed NCT05177120 - Central Sensitization in Familial Mediterranean Fever (FMF)
Active, not recruiting NCT06257342 - Physical Abilities of Teenagers With Familial Mediterranean Fever
Recruiting NCT04478409 - Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
Recruiting NCT06034795 - Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever
Completed NCT04729218 - The Movement Imagery Ability in Patients With Familial Mediterranean Fever
Terminated NCT01059279 - Heat Intolerance in the Group of FMF Patients
Enrolling by invitation NCT04724993 - Effects of Online Aerobic Exercise Training and Physical Activity Counseling in Juvenile Familial Mediterranean Fever N/A
Completed NCT03747315 - A Diagnostic Test for Familial Mediterranean Fever
Completed NCT01075906 - Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients Phase 1
Completed NCT00582907 - Rilonacept for Treatment of Familial Mediterranean Fever (FMF) Phase 2
Withdrawn NCT00323440 - Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission N/A
Not yet recruiting NCT05488561 - Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings N/A